RxDoctor Payments Data

Mary Evans, MD

Psychiatry · Kalispell, MTNPI 1649245937

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $332 of the $379 with a category attached, or 87.6%. 8 manufacturers reported payments, led by AbbVie at 29.0% of the total.

$379in general payments, 2019–2025

Across 20 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$110
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$60
  • Sunovion Pharmaceuticals Inc.$59
  • Johnson & Johnson$43
  • Neurocrine Biosciences, Inc.$36
  • Otsuka America Pharmaceutical, Inc.$35
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$33288%
  • Education$4712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$379 in reported general payments places this provider in the 70th percentile of 82 psychiatry providers in Montana.

See all psychiatry providers in Montana

Medicare billing

Part B allowed, 2024
$43,955
Medicare patients
67
Services billed
378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$78,806
Invega SustennaPaliperidone Palmitate12$26,155
VyvanseLisdexamfetamine Dimesylate16$10,219
TrintellixVortioxetine Hydrobromide18$8,965
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl26$3,592
Duloxetine Hcl156$3,569
Lisdexamfetamine Dimesylate12$3,103
Aripiprazole82$2,370
Dextroamphetamine Sulfate ErDextroamphetamine Sulfate13$1,996
Asenapine Maleate18$1,894
Oxcarbazepine15$1,412
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine44$1,257
Bupropion XlBupropion Hcl62$1,256
Venlafaxine Hcl ErVenlafaxine Hcl61$1,216
Trazodone Hcl89$1,166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$11$78,80613 claims
Johnson & JohnsonInvega Sustenna$43$26,15512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 82 psychiatry providers in Montana.

Other psychiatry in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →